Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
(Photo by Niki Kelly/Indiana Capital Chronicle) Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful prescription treatments in settings that operate largely outside state oversight
[Adobe Stock] A flurry of recent FDA announcements and legal maneuvers has placed two popular weight-loss drugs tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly) and semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) at the center of a growing squabble
A: Foundayo (orforglipron) is an oral GLP-1 receptor agonist (a daily pill)
One simple price that covers every dose
However, most have recovered after receiving intravenous fluids and anti-nausea medications
This inherently builds additional cost into the product price
